RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..2 of 2 - per page
Order by
Inno-C08001 (Carvedilol CR)
Inno-C08001 is indicated for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction More
ViaDerm - Device-Tissue BioIntegration Platform
Tissue Engineered Skin Access Device More
Displaying 1..2 of 2 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Failure of TAK442 to Meet the Primary End-point in a Phase II Study Underlines the Challenging Clinical Development Environment for Anticoagulants in Acute Coronary Syndromes
Nov 2010 - 5 pages - $500
Acute Coronary Syndromes Therapy Area Pipeline Report
Nov 2010 - 329 pages - $1,495
Congestive Heart Failure Therapy Area Pipeline Report
Nov 2010 - 539 pages - $1,495
Acute Heart Failure - Pipeline Review, Q1 2011
Feb 2011 - 29 pages - $500
Acute Coronary Syndromes - Pipeline Review, Q1 2011
Feb 2011 - 62 pages - $500
Acute Heart Failure - Pipeline Assessment and Market Forecasts to 2017
Dec 2010 - 47 pages - $2,000
Acute Heart Failure - Pipeline Review, H2 2011
Sep 2011 - 58 pages - $500
Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical Management
Feb 2008 - 220 pages - $3,495
Innovations in Cardiovascular Disease Management
May 2007 - 183 pages - $2,875
Congestive Heart Failure: Major World Markets, Volume II: Devices (Pacemaker, ICD, LVAD and Artificial Heart Markets)
Feb 2008 - 250 pages - $3,495
More Related Market Research Reports >>>

Your selection

Therapeutic target
Cardiovascular del
Acute coronary syndromes del
Congestive heart failure del
Development phase
Early Stage del

Browse By

Industry sector
Animal health
Biotechnology
Diagnostic
Drug delivery
Drug discovery
Medical device
Pharmaceutical
Research tools

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us